| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SELP; GMRP; GRMP; P-selectin; CD62 antigen-like family member P; Granule membrane protein 140; GMP-140; Leukocyte-endothelial cell adhesion molecule 3; LECAM3; Platelet activation dependent granule-external membrane protein; PADGEM; CD62P |
| Entrez GeneID | 6403 |
| WB Predicted band size | Calculated MW: 91 kDa; Observed MW: 91 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from the N-terminal region of human SELP. AA range:81-130 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于CD62P(P-选择素)抗体的3篇代表性文献摘要：
---
1. **文献名称**：*P-Selectin and platelet activation in patients with acute coronary syndromes*
**作者**：Furman MI, et al.
**摘要**：该研究通过检测急性冠脉综合征患者血小板表面CD62P的表达，发现其水平显著升高，提示CD62P抗体可作为血小板活化的生物标志物，对心血管疾病风险评估具有临床价值。
---
2. **文献名称**：*Targeting P-selectin glycoprotein ligand-1/P-selectin interactions in inflammatory disease*
**作者**：Myers DD, et al.
**摘要**：研究利用CD62P抗体阻断P-选择素与其配体(PSGL-1)的相互作用，发现可显著抑制白细胞黏附和炎症反应，为治疗血栓性静脉炎等炎症性疾病提供了实验依据。
---
3. **文献名称**：*In vivo imaging of platelet-endothelial interactions in atherosclerosis using CD62P-targeted nanoparticles*
**作者**：McCarthy JR, et al.
**摘要**：作者开发了一种靶向CD62P的抗体偶联纳米颗粒，成功用于动脉粥样硬化模型的无创成像，证实了CD62P在血管内皮活化中的关键作用，为疾病监测提供了新工具。
---
这些文献涵盖了CD62P在疾病机制、治疗靶点和诊断技术中的应用，反映了其在基础和临床研究中的广泛意义。
CD62P, also known as P-selectin, is a cell adhesion molecule expressed on activated platelets and endothelial cells. It is stored in α-granules of platelets and Weibel-Palade bodies of endothelial cells, translocating to the cell surface upon activation. CD62P mediates leukocyte rolling and adhesion to vascular surfaces during inflammation and thrombosis by binding to PSGL-1 (P-selectin glycoprotein ligand-1) on leukocytes.
CD62P antibodies are essential tools for detecting platelet activation or endothelial dysfunction in research and clinical settings. Structurally, CD62P is a transmembrane glycoprotein with an N-terminal lectin domain, an epidermal growth factor-like region, and complement regulatory protein repeats. Its expression is upregulated in thrombotic disorders (e.g., myocardial infarction, stroke), inflammatory diseases, and cancer metastasis.
In laboratory applications, anti-CD62P antibodies are used in flow cytometry to assess platelet activation status, in immunohistochemistry to visualize endothelial activation, and in functional assays to study cell adhesion mechanisms. Monoclonal antibodies targeting CD62P have also been explored for therapeutic purposes, aiming to inhibit pathological leukocyte-platelet interactions. Elevated soluble CD62P levels in plasma serve as a biomarker for vascular inflammation and hypercoagulable states. Research continues to explore its role in atherosclerosis, sepsis, and immune-mediated diseases, highlighting its dual function as a diagnostic marker and potential therapeutic target.
×
